Post-exposure prophylaxis for HIV infection

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 4, 2011, Pages 431-442

  Rey, David ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

adherence; adverse events; antiretrovirals; cost effectiveness; follow up; HIV testing; lopinavir; post exposure; prophylaxis; raltegravir; transmission risk

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PLACEBO; RALTEGRAVIR; ZIDOVUDINE;

CASE CONTROL STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FOLLOW UP; HEADACHE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LIVER TOXICITY; NAUSEA; NONHUMAN; OBSERVATIONAL STUDY; OCCUPATIONAL EXPOSURE; PERINATAL DRUG EXPOSURE; POST EXPOSURE PROPHYLAXIS; PRISONER; QUALITY ADJUSTED LIFE YEAR; RASH; REVIEW; RISK FACTOR; SEXUAL ABUSE; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SINGLE DRUG DOSE; SKIN TOXICITY; UNSAFE SEX;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, VIRAL; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HUMANS; POST-EXPOSURE PROPHYLAXIS; SAFETY; TIME FACTORS;

EID: 79955116011     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.20     Document Type: Review

References (79)

1. Hall HI, Song R, Rhodes P et al. Estimation of HIV incidence in the United States. JAMA 300(5), 520-529 (2008).
2. LaFon SW, Mooney BD, McMullen JP et al. A double-blind, placebo-controlled study of the safety and efficacy of retrovir (zidovudine, ZDV) as a chemoprophylactic agent in health care workers (HCW) exposed to HIV. Presented at: 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, GA, USA, 21-24 October 1990.
3. Cardo DM, Culver DH, Ciesielski CA et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N. Engl. J. Med. 337(21), 1485-1490 (1997). (Pubitemid 27495773)
4. Tsai CC, Emau P, Follis KE et al. Effectiveness of post-inoculation (R)-9-(2- phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficicency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J. Virol. 72(5), 4265-4273 (1998). (Pubitemid 28188732)
5. Otten RA, Smith DK, Adams DR et al. Efficacy of post-exposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).J. Virol. 74(20), 9771-9775 (2000).
6. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intra-epithelial dendritic cells. J. Virol. 74(13), 6087-6095 (2000). (Pubitemid 30412980)
7. Le Grand R, Vaslin B, Larghero J et al. Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera. AIDS 14(12), 1864-1866 (2000).
8. Emau P, Jiang Y, Agy MB, Tian B, Bekele G, Tsai CC. Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention. AIDS Res. Ther. 3, 29 (2006).
9. Garcia-Lerma G, Cong ME, Mitchell J et al. Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci. Transl. Med. 2(14), 14ra4 (2010).
10. Veazey R, Ketas T, Dufour J, Klasse P, Moore J. Protection of rhesus macaques from vaginal infection by maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010.
11. Taha TE, Kumwenda NI, Gibbons A et al. Short post-exposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 362(9391), 1171-1177 (2003). (Pubitemid 37255341)
12. Gray GE, Urban M, Chersich MF et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS 19(12), 1289-1297 (2005). (Pubitemid 41224898)
13. Wade NA, Birkhead GS, Warren BL et al. Abbreviated regimens of Zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N. Engl. J. Med. 339(20), 1409-1414 (1998). (Pubitemid 28516063)
14. Schechter M, Do Lago RF, Mendelsohn AB et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J. Acquir. Immune Defic. Syndr. 35(5), 519-525 (2004). (Pubitemid 38420661)
15. Hawkins DA, Asboe D, Barlow K et al. Seroconversion to HIV-1 following a needlestick injury despite combination postexposure prophylaxis. J. Infect. 43(1), 12-15 (2001). (Pubitemid 33019633)
16. Beltrami EM, Luo CC, de la Torre N, Cardo DM. Transmission of drug-resistant HIV after an occupational exposure despite postexposure prophylaxis with a combination drug regimen. Infect. Control Hosp. Epidemiol. 23(6), 345-348 (2002). (Pubitemid 34774368)
17. Prada N, Davis B, Jean-Pierre P et al. Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course. J. Acquir. Immune Defic. Syndr. 49(2), 119-122 (2008).
18. Roland ME, Neilands TB, Krone MR et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin. Infect. Dis. 41(10) 1507-1513 (2005). (Pubitemid 41579997)
19. Fournier S, Maillard A, Molina JM. Failure of postexposure prophylaxis after sexual exposure to HIV. AIDS 15(3), 430-431 (2001).
20. Bryant J, Baxter L, Hird S. Non-occupational postexposure prophylaxis for HIV: a systematic review. Health Technol. Assess. 13(14), 1-60 (2009).
21. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996), 1168-1174 (2010).
22. Grant RM, Lama JR, Anderson PL et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363(27), 2587-2599 (2010).
23. Van der Straten A, Gomez CA, Saul J, Quan J, Padian N. Sexual risk behaviors among heterosexual HIV serodiscordant couples in the era of post-exposure prevention and viral suppressive therapy. AIDS 14(4), F47-F54 (2000). (Pubitemid 30182456)
24. Sonder G, Van den Hoek A, Regez RM et al. Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000-2004. Sex. Transm. Dis. 34(5), 288-293 (2006). (Pubitemid 46707481)
25. Donnell D, Mimiaga MJ, Mayer K, Chesney M, Koblin B, Coates T. Use of non-occupational post-exposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trial. AIDS Behav. 14(5), 1182-1189 (2010).
26. Poynten IM, Jin F, Mao L et al. Nonoccupational postexposure prophylaxis, subsequent risk behavior and HIV incidence in a cohort of Australian homosexual men. AIDS 23(9), 1119-1126 (2009).
27. Quirino T, Niero F, Ricci E et al. HAART tolerability: postexposure prophylaxis in healthcare workers versus treatment in HIV-infected patients. Antivir. Ther. 5(3), 195-197 (2000).
28. Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin. Infect. Dis. 39(3), 395-401 (2004). (Pubitemid 39050489)
29. Sonder G, Prins JM, Regez RM et al. Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance. Sex. Transm. Dis. 37(12), 1-6 (2010).
30. Tissot F, Erard V, Dang T, Cavassini M. Nonoccupational HIV post-exposure prophylaxis: a 10-year retrospective analysis. HIV Med. 11(9), 584-592 (2010).
31. Rabaud C, Burty C, Grandidier M et al. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection. Clin. Infect. Dis. 40(2), 303-305 (2005). (Pubitemid 40110678)
32. Tosini W, Muller P, Prazuck T et al. Tolerability of HIV post-exposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation. AIDS 24(15), 2375-2380 (2010).
33. Pavel S, Burty C, Alcaraz I et al. Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen. AIDS 21(2), 268-269 (2007). (Pubitemid 46036950)
34. Diaz-Brito V, Leon A, Knobel H et al. An open randomized multicenter clinical trial comparing zidovudine/lamivudine plus lopinavir/ritonavir or plus atazanavir used as post-exposure prophylaxis for HIV infection. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010.
35. Burty C, Prazuck T, Truchetet F et al. Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV. AIDS Patient Care STDs 24(1), 1-3 (2010).
36. Feldt T, Oette M, Wenning M, Kroidl A, Häussinger D. Haemodynamic crisis and reversible multiorgan failure caused by HIV post-exposure prophylaxis after needle-stick injury in a health care worker. HIV Med. 5(2), 125-127 (2004). (Pubitemid 38404667)
37. Patel SM, Johnson S, Belknap SM, Chan J, Sha BE, Bennett C. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 35(2), 120-125 (2004). (Pubitemid 38133733)
38. McKoy JM, Bennett CL, Scheetz MH et al. Hepatotoxicity associated with long-versus short-course HIV prophylactic nevirapine use: a systematic review and meta-analysis from the research on adverse drug events and reports (RADAR) project. Drug Saf. 32(2), 147-158 (2009).
39. Rey D, Partisani M, Hess-Kempf G et al. Tolerance of a short course of nevirapine, associated with 2 nucleoside analogues, in postexposure prophylaxis of HIV. J. Acquir. Immune Defic. Syndr. 37(4), 1454-1456 (2004). (Pubitemid 39602334)
40. Livrozet JM, Berra N, Ravaux I et al. The Bill trial: a pilot study assessing the safety of a shortcourse nevirapine (NVP)- containing regimen as a post exposure prophylaxis (PEP).Programs and Abstracts of the 6th International Congress of Drug Therapy in HIV Infection. Glasgow, UK, 17-21 November 2002 (Abstract p58).
41. Siegel MO, Kan VLK, Benator DA. Raltegravir for postexposure prophylaxis following occupational exposure to HIV. AIDS 22(18), 2552-2553 (2008).
42. Baraboutis IG, Papastamopoulos V, Georgiou O et al. Expanded postexposure prophylaxis for simultaneous multiple source HIV exposure in a health-care worker. Intern. J. STD AIDS 21(2), 147-148 (2010).
43. Mayer K, Mimiaga M, Gelman M, Trufant J, Maynard S, McMorrow P. Tenofovir DF/ emtricitabine/raltegravir (TDF/FTC/RAL) appears safe and well-tolerated for non-occupational post-exposure prophylaxis (NPEP).Programs and Abstracts of the 5th Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19-22 July 2009, (Abstract WEAC104).
44. Méchai F, Quertainmont Y, Sahali S, Delfraissy JF, Ghosn J. Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multi-resistant HIV-infected source person. J. Med. Virol. 80(1), 9-10 (2008). (Pubitemid 350220083)
45. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost- effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch. Intern. Med. 164(1), 46-54 (2004). (Pubitemid 38067388)
46. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS 18(15), 2065-2073 (2004). (Pubitemid 39463360)
47. Herida M, Larsen C, Lot F et al. Cost-effectiveness of HIV post-exposure prophylaxis in France. AIDS 20(13), 1753-1761 (2006). (Pubitemid 44299367)
48. Guinot D, Ho MT, Poynten IM et al. Cost-effectiveness of HIV nonoccupational post-exposure prophylaxis in Australia. HIV Med. 10(4), 199-208 (2009).
49. Roland ME. Enhancing the potential benefits of HIV post-exposure prophylaxis. AIDS 20(14), 1889-1890 (2006). (Pubitemid 44358908)
50. Fox J, Fidler S. Sexual transmission of HIV-1. Antivir. Res. 85(1), 276-285 (2010).
51. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm. Rep. 54(9), 1-17 (2005).
52. Varghese B, Maher JE, Peterman TA, Branson BM, Steketee RW. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex. Transm. Dis. 29(1), 38-43 (2002). (Pubitemid 34074430)
53. Centers for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm. Rep. 54(2), 1-20 (2005).
54. Jin F, Jansson J, Law M et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS 24(6), 907-913 (2010).
55. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2, e298 (2005).
56. Bailey RC, Moses S, Parker CB et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369(9562), 643-656 (2007). (Pubitemid 46281312)
57. Gray RH, Kigozi G, Serwadda D et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369(9562), 657-666 (2007).
58. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 376(9737), 285-301 (2010).
59. Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 357(9266), 1397-1401 (2001). (Pubitemid 32455367)
60. Abdala N, Reyes R, Carney JM, Heimer R. Survival of HIV-1 in syringes: effects of temperature during storage. Subst. Use Misuse. 35(10), 1369-1383 (2000). (Pubitemid 30484353)
61. Cheret A, Poggi C, Tamalet C et al. Is post-exposure prophylaxis necessary in cases with blood exposure through fight when HIV status is unknown? Programs and Abstracts of the 5th Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19-22 July 2009 (Abstract CDC052).
62. Bartholomew CF, Jones AM. Huma bites: a rare risk factor for HIV transmission. AIDS 20(4), 631-632 (2006). (Pubitemid 43731612)
63. HIV Prophylaxis Following Occupational Exposure. New York State Department of Health AIDS Institute, Albany, NY, USA (2008).
64. Rey D, L'Héritier A, Lang JM. Severe ototoxicity in a health care worker who received post- exposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV. Clin. Infect. Dis. 34(3), 418-419 (2002). (Pubitemid 34062249)
65. Landovitz JL, Currier JS. Postexposure prophylaxis for HIV infection. N. Engl. J. Med. 361(18), 1768-1775 (2009).
66. Bentz L, Enel P, Dunais B et al. Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: a randomized controlled trial. AIDS Care 22(12), 1509-1516 (2010).
67. Bakhru A, Mallinger JB, Fox MC. Postexposure prophylaxis for victims of sexual assault: treatments and attitudes of emergency department physicians. Contraception 82(2), 168-173 (2010).
68. Griffith WF, Ackerman GE, Zoellner CL et al. Sexual assault: a report on human immunodeficiency virus postexposure prophylaxis. Obstet. Gynecol. Int. DOI:10.1155/2010/196963 (2010) (Epub ahead of print).
69. Abrahams N, Jewkes R, Lombard C et al. Impact of telephonic psycho-social support on adherence to post-exposure prophylaxis (PEP) after rape. AIDS Care 22(10), 1173-1181 (2010).
70. Azodo CC, Ehigiator O, Ojo MA. Occupational risks and hepatitis B vaccination status of dental auxiliaries in Nigeria. Med. Princ. Pract. 19(5), 364-366 (2010).
71. Ehui E, Kra O, Ouattara I et al. Management of accidental exposure to blood in the Treichville teaching hospital, Abidjan (Côte-d'Ivoire).Med. Mal. Infect. 37(Suppl. 3) S251-S256 (2007).
72. Siika AM, Nyandiko WM, Mwangi A et al. The structure and outcomes of a HIV postexposure prophylaxis program in a high HIV prevalence setup in Western Kenya. J. Acquir. Immune Defic. Syndr. 51(1), 47-53 (2009).
73. Kilonzo N, Theobald SJ, Nyamato E et al. Delivering post-rape care services: Kenya's experience in developing integrated services. Bull. World Health Organ. 87(7), 555-559 (2009).
74. Birdthistle IJ, Floyd S, Mwanasa S et al. Child sexual abuse and links to HIV and orphanhood in urban Zimbabwe. J. Epidemiol. Community Health DOI:10.1136/jech.2009.094359 (2010) (Epub ahead of print).
75. Chesshyre EL, Molyneux EM. Presentation of child sexual abuse cases to Queen Elizabeth Central Hospital following the establishment of an HIV post-exposure prophylaxis programmme. Malawi Med. J. 21(2), 54-58 (2009).
76. Ehui E, Tanon A, Guié P et al. Antiretroviral prophylaxis after non-occupational exposure to HIV in Abidjan (Cote d'Ivoire).Med. Mal. Infect. 40(10), 574-581 (2010).
77. Van der Maaten GC, Nyirenda M, Beadsworth MJ et al. Post exposure prophylaxis of HIV transmission after occupational injuries in Queen Elizabeth Central Hospital, Blantyre, Malawi, 2003-2008. Malawi Med. J. 22(1), 15-19 (2010).
78. Wohl AR, Johnson D, Jordan W et al. High-risk behaviors during incarceration in African-American men treated for HIV at three Los Angeles public medical centers. J. Acquir. Immune Defic. Syndr. 24(4), 386-392 (2000).
79. Havens PL. Committee on Pediatric AIDS. Postexposure prophylaxis in children and adolescents for nonoccupational exposure to human immunodeficiency virus. Pediatrics 111(6), 1475-1489 (2003). (Pubitemid 36682292)